Table 2.
Cardiovascular disease (CVD) risk factors in circulation in Wistar rats fed the different oil supplements
| |
EPA/DHA 1:1 |
EPA/DHA 2:1 |
EPA/DHA 1:2 |
Soybean oil |
Linseed oil |
|||
|---|---|---|---|---|---|---|---|---|
|
Biomarkers |
Mean ± SD |
Mean ± SD |
Mean ± SD |
p |
Mean ± SD |
P |
Mean ± SD |
p |
| CV RISK FACTORS | ||||||||
|
Lipid profile | ||||||||
| TG (mg/dL) |
86.3 ± 65.1 |
124.5 ± 102.2 |
83.1 ± 10.4 |
|
108.5 ± 51.9 |
|
73.5 ± 25.2 |
|
| CHOL (mg/dL) |
93.3 ± 26.5 |
98.0 ± 14.8 |
112.3 ± 20.8 |
|
125.8 ± 16.5 |
|
118.5 ± 13.5 |
|
| LDLc (mg/dL) |
7.64 ± 3.3 |
7.4 ± 0.8 |
8.30 ± 1.3 |
|
10.39 ± 2.2 |
|
7.4 ± 1.6 |
|
| HDLc (mg/dL) |
37.4 ± 11.1 |
50.4 ± 25.9 |
47.3 ± 8.1 |
|
51.3 ± 7.8 |
|
46.8 ± 5.5 |
|
| LDLc/HDLc |
0.19 ± 0.5 |
0.20 ± 0.01 |
0.17 ± 0.01 |
|
0.20 ± 0.2 |
|
0.19 ± 0.1 |
|
| ApoA1 (mg/mL) |
43.0 ± 11.4 |
51.7 ± 11.9 |
47.9 ± 13.8 |
|
51.4 ± 13.3 |
|
30.6 ± 2.1 |
|
| ApoB100 (mg/mL) |
116.5 ± 16.8 |
137.0 ± 6.4 |
139.4 ± 23.8 |
|
126.8 ± 13.9 |
|
152.7 ± 35.7 |
|
| ApoB100/ApoA1 |
2.79 ± 0.51 |
2.75 ± 0.54 |
3.10 ± 1.01 |
|
2.67 ± 1.11 |
|
5.02 ± 1.29 |
a0.029 |
| |
|
|
|
|
|
|
b0.019 |
|
| |
|
|
|
|
|
|
d0.029 |
|
|
Glycaemia | ||||||||
| Glucose increase (mmol/L) |
-0.75 ± 0.42 |
-0.15 ± 0.34 |
0.27 ± 0.49 |
a0.001 |
0.53 ± 0.25 |
a < 0.001 |
- 0.20 ± 0.31 |
d0.032 |
| Glycated Haemoglobin (%) |
4.14 ± 0.24 |
4.43 ± 0.72 |
4.17 ± 0.30 |
|
6.39 ± 0.99 |
a0.003 |
6.34 ± 1.84 |
a0.025 |
| |
|
|
|
|
b0.007 |
|
b0.05 |
|
| |
|
|
|
|
c0.004 |
|
c0.032 |
|
| Insulin increase (ng/mL) |
1.40 ± 0.8 |
0.15 ± 1.90 |
0.42 ± 0.4 |
|
0.9 ± 1.5 |
|
0.41 ± 0.5 |
|
| Homa index | 7.0 ± 3.0 |
4.1 ± 1.8 |
3.8 ± 1.5 |
|
6.9 ± 3.8 |
|
2.9 ± 1.1 |
a0.004 |
| d0.032 | ||||||||
The data are expressed as mean ± SD (standard deviation). a: differences with respect to EPA/DHA 1:1 supplementation; b: differences with respect to EPA/DHA 2:1 supplementation; c: differences with respect to EPA/DHA 1:2 supplementation; d: differences with respect to soybean oil supplementation.